Humana (NYSE:HUM) Updates FY 2026 Earnings Guidance

Humana (NYSE:HUM) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 9.000- for the period, compared to the consensus earnings per share estimate of 8.780. The company issued revenue guidance of $160.0B-, compared to the consensus revenue estimate of $162.6 billion.

Humana Trading Up 3.0%

Shares of Humana stock opened at $230.32 on Wednesday. The company has a market capitalization of $27.65 billion, a P/E ratio of 23.45, a price-to-earnings-growth ratio of 2.40 and a beta of 0.44. The stock has a fifty day simple moving average of $186.35 and a 200 day simple moving average of $227.34. Humana has a 12-month low of $163.11 and a 12-month high of $315.35. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the business earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, sell-side analysts anticipate that Humana will post 9.05 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 26th. This represents a $3.54 annualized dividend and a yield of 1.5%. Humana’s payout ratio is 36.05%.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of recent analyst reports. Truist Financial upped their price objective on shares of Humana from $200.00 to $220.00 and gave the stock a “hold” rating in a research report on Monday, April 13th. JPMorgan Chase & Co. cut their target price on Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. Guggenheim reduced their target price on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Robert W. Baird decreased their price target on Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $344.00 price objective on shares of Humana in a research note on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $222.09.

Insider Activity at Humana

In other news, insider Sanjay K. Shetty purchased 810 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was bought at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider owned 11,657 shares of the company’s stock, valued at $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by corporate insiders.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: New strategic pharmacy tie-up with Mark Cuban’s Cost Plus Drugs expands CenterWell’s distribution and employer-focused drug offerings — a potential margin and growth tailwind if it scales. Humana partners with Mark Cuban’s Cost Plus Drugs on technology, distribution
• Positive Sentiment: Medicare Advantage payment rules for 2027 look modestly favorable (CMS projected ~2.48% increase), improving revenue visibility for MA-focused insurers like Humana and supporting sentiment into earnings. Humana rises 3.9% ahead of earnings as Medicare Advantage rate outlook supports sentiment
• Neutral Sentiment: Q1 2026 earnings release is scheduled for April 29 — a near-term catalyst that’s driving positioning; investors will focus on medical-cost trends, membership metrics and FY guidance. Earnings to watch: Humana (HUM) reports Q1 results tomorrow
• Neutral Sentiment: Humana is rallying alongside UnitedHealth as the managed?care sector rebounds in April; part of the move reflects broader sector rotation rather than company?specific news. UnitedHealth and Humana Soar in April: Which Healthcare Stock Is Winning and Why
• Negative Sentiment: Analyst and media caution: Humana’s share performance has been volatile this year due to uncertainty around how much the government will pay Medicare Advantage plans — downside risk remains if reimbursement pressure reappears or guidance disappoints. Humana Earnings Could Signal If More Medicare Advantage Members Is a Good Thing

Hedge Funds Weigh In On Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Revolve Wealth Partners LLC purchased a new stake in shares of Humana during the 4th quarter valued at approximately $202,000. Sivia Capital Partners LLC boosted its holdings in Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after buying an additional 452 shares during the period. DRW Securities LLC purchased a new position in Humana in the 4th quarter valued at approximately $244,000. VARCOV Co. bought a new stake in Humana during the 4th quarter valued at $231,000. Finally, HUB Investment Partners LLC bought a new stake in Humana during the 2nd quarter valued at $212,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.